Alzheimer's Disease

POST GRAD: The purpose of this study is to compare the effects, good or bad, of long term gantenerumab on subjects with prodromal or mild Alzheimer's disease. 

This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois.  AD patients and their caregivers who are living in private homes will be recruited.  Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13  The patient and caregiver dyad will be encouraged

I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior.  Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.

I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior.  Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.

ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.

ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.